近期,一些正在开发的细胞疗法相继在临床后期取得积极结果,这给行业增添了一份信心。其中,Mesoblast公司异基因间充质干细胞候选产品remestemcel-L已于今年4月在美国提交生物制品许可申请(BLA),Gamida Cell公司脐带血干细胞疗法omidubicel治疗高危恶性血液癌症患者的3期临床,也于今年5月获得积极结果。
尽管干细胞疗法仍然面临不少挑战,但我们相信随着新一代干细胞疗法离临床应用越接近,科学家们对需要解决的挑战的认知就越清晰。我们期待这些新型干细胞疗法能改变病患的治疗,让他们的疾病能更好地得到控制。
参考资料:
[1] Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID. Retrieved February 22, 2019, from https://globenewswire.com/news-release/2019/02/22/1740293/0/en/Orchard-Therapeutics-Presents-Two-Year-Follow-Up-Data-Versus-Historical-Control-from-Registrational-Trial-of-OTL-101-for-the-Treatment-of-ADA-SCID.html
[2] Bayer acquires BlueRock Therapeutics to build leading position in cell therapy, Retrieved August 8, 2019, from https://media.bayer.com/baynews/baynews.nsf/id/Bayer-acquires-BlueRock-Therapeutics-to-build-leading-position-in-cell-therapy
[3] First iPSC-Derived CAR T-Cell Therapy Created by Kyoto University CiRA and Takeda Collaboration Enters Process Development Toward Clinical Testing, Retrieved July 16, 2019, from https://www.cira.kyoto-u.ac.jp/e/pressrelease/news/190716-150000.html
[4] Novo Nordisk increases commitment to stem cell-based therapies
[5] Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells. Retrieved April 22, 2020, from https://www.businesswire.com/news/home/20200421005170/en/
[6] Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies. Retrieved 2020-05-12, from https://www.businesswire.com/news/home/20200512005264/en
[7] Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies, Retrieved Apr 3, 2020, from https://www.globenewswire.com/news-release/2020/04/02/2011136/0/en/Fate-Therapeutics-Announces-Worldwide-Collaboration-with-Janssen-for-Novel-iPSC-derived-Cell-based-Cancer-Immunotherapies.html
原标题:诺奖级发现,“世界十大科技成就”之首,我们距新一代干细胞疗法还有多远?